Stock comparison
GILEAD SCIENCES, INC. is 19.8x more valuable than Immunovant, Inc. by market capitalization ($167.41 B vs $8.44 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
GILD is larger
GILEAD SCIENCES, INC. is 19.8x more valuable than Immunovant, Inc. by market capitalization ($167.41 B vs $8.44 B).
Market value leader
GILD
GILEAD SCIENCES, INC. is 19.8x more valuable than Immunovant, Inc. by market capitalization ($167.41 B vs $8.44 B).
Profit leader
GILD
IMVT: -$505.61M vs GILD: $8.51B.
| Metric | IMVT | GILD |
|---|---|---|
| Market cap | $8.44 B | $167.41 B |
| US-listed rank | #1062 | #92 |
| Revenue (latest FY) | - | $29.44B |
| Net income (latest FY) | -$505.61M | $8.51B |
| Net margin | - | 28.9% |
| P/E (trailing FY) | - | 19.7x |
| SEC filings | 611 | 968 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
GILEAD SCIENCES, INC. is 19.8x more valuable than Immunovant, Inc. by market capitalization ($167.41 B vs $8.44 B).
Full pages: Immunovant, Inc. and GILEAD SCIENCES, INC., or browse the full rankings.